🚀 VC round data is live in beta, check it out!
Tenaya Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Tenaya Therapeutics and similar public comparables like Curatis Holding, Captor Therapeutics, Macrogenics, Genelux and more.
Tenaya Therapeutics Overview
About Tenaya Therapeutics
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
Founded
2016
HQ
Employees
97
Website
Financials (LTM)
EV
$77M
Tenaya Therapeutics Financials
Tenaya Therapeutics reported last 12-month revenue of $2M and negative EBITDA of ($75M).
In the same LTM period, Tenaya Therapeutics generated $721K in gross profit, ($75M) in EBITDA losses, and had net loss of ($90M).
Revenue (LTM)
Tenaya Therapeutics P&L
In the most recent fiscal year, Tenaya Therapeutics reported revenue of — and EBITDA of ($71M).
Tenaya Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $721K | XXX | — | XXX | XXX | XXX |
| Gross Margin | 40% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($75M) | XXX | ($71M) | XXX | XXX | XXX |
| EBITDA Margin | (4177%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (4982%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($90M) | XXX | ($91M) | XXX | XXX | XXX |
| Net Margin | (4973%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Tenaya Therapeutics Stock Performance
Tenaya Therapeutics has current market cap of $122M, and enterprise value of $77M.
Market Cap Evolution
Tenaya Therapeutics' stock price is $0.56.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $77M | $122M | 0.0% | XXX | XXX | XXX | $-0.42 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTenaya Therapeutics Valuation Multiples
Tenaya Therapeutics trades at 42.8x EV/Revenue multiple, and (1.0x) EV/EBITDA.
EV / Revenue (LTM)
Tenaya Therapeutics Financial Valuation Multiples
As of March 21, 2026, Tenaya Therapeutics has market cap of $122M and EV of $77M.
Equity research analysts estimate Tenaya Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tenaya Therapeutics has a P/E ratio of (1.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $122M | XXX | $122M | XXX | XXX | XXX |
| EV (current) | $77M | XXX | $77M | XXX | XXX | XXX |
| EV/Revenue | 42.8x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (1.0x) | XXX | (1.1x) | XXX | XXX | XXX |
| EV/EBIT | (0.9x) | XXX | (0.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 106.9x | XXX | — | XXX | XXX | XXX |
| P/E | (1.4x) | XXX | (1.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Tenaya Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Tenaya Therapeutics Margins & Growth Rates
Tenaya Therapeutics' revenue in the last 12 month grew by 262%.
Tenaya Therapeutics' revenue per employee in the last FY averaged $0.0M.
Tenaya Therapeutics' rule of 40 is (3915%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tenaya Therapeutics' rule of X is (3522%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Tenaya Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 262% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (4177%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | 25% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (3915%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (3522%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1537% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3836% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Tenaya Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Curatis Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Captor Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Macrogenics | XXX | XXX | XXX | XXX | XXX | XXX |
| Genelux | XXX | XXX | XXX | XXX | XXX | XXX |
| Cantargia | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tenaya Therapeutics M&A Activity
Tenaya Therapeutics acquired XXX companies to date.
Last acquisition by Tenaya Therapeutics was on XXXXXXXX, XXXXX. Tenaya Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Tenaya Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTenaya Therapeutics Investment Activity
Tenaya Therapeutics invested in XXX companies to date.
Tenaya Therapeutics made its latest investment on XXXXXXXX, XXXXX. Tenaya Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Tenaya Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Tenaya Therapeutics
| When was Tenaya Therapeutics founded? | Tenaya Therapeutics was founded in 2016. |
| Where is Tenaya Therapeutics headquartered? | Tenaya Therapeutics is headquartered in United States. |
| How many employees does Tenaya Therapeutics have? | As of today, Tenaya Therapeutics has over 97 employees. |
| Who is the CEO of Tenaya Therapeutics? | Tenaya Therapeutics' CEO is Faraz Ali. |
| Is Tenaya Therapeutics publicly listed? | Yes, Tenaya Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Tenaya Therapeutics? | Tenaya Therapeutics trades under TNYA ticker. |
| When did Tenaya Therapeutics go public? | Tenaya Therapeutics went public in 2021. |
| Who are competitors of Tenaya Therapeutics? | Tenaya Therapeutics main competitors are Curatis Holding, Captor Therapeutics, Macrogenics, Genelux. |
| What is the current market cap of Tenaya Therapeutics? | Tenaya Therapeutics' current market cap is $122M. |
| What is the current revenue of Tenaya Therapeutics? | Tenaya Therapeutics' last 12 months revenue is $2M. |
| What is the current revenue growth of Tenaya Therapeutics? | Tenaya Therapeutics revenue growth (NTM/LTM) is 262%. |
| What is the current EV/Revenue multiple of Tenaya Therapeutics? | Current revenue multiple of Tenaya Therapeutics is 42.8x. |
| Is Tenaya Therapeutics profitable? | No, Tenaya Therapeutics is not profitable. |
| What is the current EBITDA of Tenaya Therapeutics? | Tenaya Therapeutics has negative EBITDA and is not profitable. |
| What is Tenaya Therapeutics' EBITDA margin? | Tenaya Therapeutics' last 12 months EBITDA margin is (4177%). |
| What is the current EV/EBITDA multiple of Tenaya Therapeutics? | Current EBITDA multiple of Tenaya Therapeutics is (1.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.